Tao Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tao Yan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Nan Zhang
School of Public Health, Inner Mongolia Medical University, Hohhot, China
2 shared publications - Xingguang Zhang
School of Public Health, Inner Mongolia Medical University, Hohhot, China
2 shared publications Chunfa Zhang
School of Public Health Inner Mongolia Medical University Hohhot China
1 shared publication- Haitao Ju
Department of Neurosurgery, The Affiliated Hospital of Inner Mongolia Medical University, 010030 Hohhot, Inner Mongolia, China
1 shared publication Jinli Yan
School of Public Health Inner Mongolia Medical University Hohhot China
1 shared publicationKai Wang
Department of Neurosurgery Affiliated Hospital of Inner Mongolia Medical University Hohhot China
1 shared publication
Latest Publications
- Open Access
- 27 May 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (5) , 36363
Low-Density Lipoprotein Cholesterol Reductions of not Less Than 60 mg/dL Prevent Hemorrhagic Stroke in Hypertensive Populations: A Meta-analysis
Background: The association between low-density lipoprotein cholesterol (LDL-C) levels and the risk of hemorrhagic stroke (HS) detected through different blood pressure statuses remains unclear. Hence, we systematically evaluated the association between LDL-C and HS in populations with and without hypertension. Methods: We searched PubMed, Cochrane Library, and Embase databases for articles written in English. Only prospective design or randomized controlled trials (RCTs) reporting effect estimates with 95% confidence intervals (CIs) for the relationship between LDL-C and HS were included. We pooled risk ratios (RRs) stratified by blood pressure status and dose–response analyses with a two-stage generalized least squares for trend estimation (GLST) model. Finally, we compared the lower and optimal groups to find the effect of very low LDL-C levels on the risk of HS. Results: We included seven randomized controlled trials and 9 prospective cohort studies involving 304,763 participants with 2125 (0.70%) HS events. The non-linear trend suggested that LDL-C levels of approximately 80 mg/dL among hypertensive patients and 115 mg/dL among non-hypertensive patients had the lowest risk of HS. Meanwhile, continually lowering LDL-C levels under the optimal (80 mg/dL for hypertensive patients and 115 mg/dL for non- hypertensive patients) LDL-C level would increase the risk of HS in the hypertensive population (RR = 1.84, 95% CI: 1.36–2.50) but not in the non-hypertensive population (RR = 1.15, 95% CI: 0.97–1.36). Conclusions: The risk of HS can be effectively reduced by controlling LDL-C levels to 60–80 mg/dL in the hypertensive population and 115 mg/dL in the non-hypertensive population. The safety range of controlling LDL-C levels to protect against HS among hypertensive patients is narrower than that among the non-hypertensive population. Additionally, controlling blood pressure might play a positive role in safeguarding against HS by lowering LDL-C levels.
- 27 May 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (5) , 36363
Open AccessLow-Density Lipoprotein Cholesterol Reductions of not Less Than 60 mg/dL Prevent Hemorrhagic Stroke in Hypertensive Populations: A Meta-analysis
Background: The association between low-density lipoprotein cholesterol (LDL-C) levels and the risk of hemorrhagic stroke (HS) detected through different blood pressure statuses remains unclear. Hence, we systematically evaluated the association between LDL-C and HS in populations with and without hypertension. Methods: We searched PubMed, Cochrane Library, and Embase databases for articles written in English. Only prospective design or randomized controlled trials (RCTs) reporting effect estimates with 95% confidence intervals (CIs) for the relationship between LDL-C and HS were included. We pooled risk ratios (RRs) stratified by blood pressure status and dose–response analyses with a two-stage generalized least squares for trend estimation (GLST) model. Finally, we compared the lower and optimal groups to find the effect of very low LDL-C levels on the risk of HS. Results: We included seven randomized controlled trials and 9 prospective cohort studies involving 304,763 participants with 2125 (0.70%) HS events. The non-linear trend suggested that LDL-C levels of approximately 80 mg/dL among hypertensive patients and 115 mg/dL among non-hypertensive patients had the lowest risk of HS. Meanwhile, continually lowering LDL-C levels under the optimal (80 mg/dL for hypertensive patients and 115 mg/dL for non- hypertensive patients) LDL-C level would increase the risk of HS in the hypertensive population (RR = 1.84, 95% CI: 1.36–2.50) but not in the non-hypertensive population (RR = 1.15, 95% CI: 0.97–1.36). Conclusions: The risk of HS can be effectively reduced by controlling LDL-C levels to 60–80 mg/dL in the hypertensive population and 115 mg/dL in the non-hypertensive population. The safety range of controlling LDL-C levels to protect against HS among hypertensive patients is narrower than that among the non-hypertensive population. Additionally, controlling blood pressure might play a positive role in safeguarding against HS by lowering LDL-C levels.
- Open Access
- 29 August 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 26 (11) , 1219-1227
Risk analysis of blood pressure changes on cardiovascular disease in Chinese population
The study aimed to assess the impact of changes in blood pressure on cardiovascular events in the Chinese population. It enrolled 33 179 Chinese participants aged ≥35 years (57.1% women) without CVD at baseline. BP status was defined according to the 2017 ACC/AHA hypertension guidelines. The type of BP change was defined as change in BP status from baseline to the end of follow‐up, included stable BP <130/80, <130/80 to ≥130/80, ≥130/80 to <130/80 mm Hg, persistent BP ≥130/80 mm Hg. The hazard ratio (HR) of incident CVD by change in BP category was estimated using Cox proportional hazards and Fine–Gray models. During median follow‐up of 3.17 years, 2023 CVD events occurred. Compared with BP <120/80, 120–129/<80 mm Hg at baseline (HR = 1.66, 95% CI: 1.09–2.53), 130–139/80–89 mm Hg (HR = 1.35, 95% CI: 0.94–1.95), and ≥140/90 mm Hg (HR = 2.46, 95% CI: 1.78–3.40) were risk factors for CVD. Compared with the group with stable BP <130/80 mm Hg, the risk of CVD was 1.88 (95% CI: 1.40–2.53) in the group with persistent BP ≥130/80 mm Hg and 1.40 (95% CI: 1.01–1.94) in the group of BP decreased to <130/80 mm Hg. These results showed that BP 120–129/<80, 130–139/80–89, and ≥140/90 mm Hg were associated with a high risk of CVD. Over time, persistent BP ≥130/80 mm Hg increased the risk of CVD, but a return to <130/80 mm Hg from hypertension decreased the risk of CVD.
- 29 August 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 26 (11) , 1219-1227
Open AccessRisk analysis of blood pressure changes on cardiovascular disease in Chinese population
The study aimed to assess the impact of changes in blood pressure on cardiovascular events in the Chinese population. It enrolled 33 179 Chinese participants aged ≥35 years (57.1% women) without CVD at baseline. BP status was defined according to the 2017 ACC/AHA hypertension guidelines. The type of BP change was defined as change in BP status from baseline to the end of follow‐up, included stable BP <130/80, <130/80 to ≥130/80, ≥130/80 to <130/80 mm Hg, persistent BP ≥130/80 mm Hg. The hazard ratio (HR) of incident CVD by change in BP category was estimated using Cox proportional hazards and Fine–Gray models. During median follow‐up of 3.17 years, 2023 CVD events occurred. Compared with BP <120/80, 120–129/<80 mm Hg at baseline (HR = 1.66, 95% CI: 1.09–2.53), 130–139/80–89 mm Hg (HR = 1.35, 95% CI: 0.94–1.95), and ≥140/90 mm Hg (HR = 2.46, 95% CI: 1.78–3.40) were risk factors for CVD. Compared with the group with stable BP <130/80 mm Hg, the risk of CVD was 1.88 (95% CI: 1.40–2.53) in the group with persistent BP ≥130/80 mm Hg and 1.40 (95% CI: 1.01–1.94) in the group of BP decreased to <130/80 mm Hg. These results showed that BP 120–129/<80, 130–139/80–89, and ≥140/90 mm Hg were associated with a high risk of CVD. Over time, persistent BP ≥130/80 mm Hg increased the risk of CVD, but a return to <130/80 mm Hg from hypertension decreased the risk of CVD.